Erratum to: Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab [PDF]
, 2014 Vittorio Fusco +2 more
openalex +1 more source
The use of romosozumab versus denosumab in patients with osteoporosis. [PDF]
Rev Assoc Med Bras (1992)Floriano I, Silvinato A, Bernardo WM.
europepmc +1 more source
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases. [PDF]
J Clin MedAliyev V +9 more
europepmc +1 more source
Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report [PDF]
, 2015 Allen R. Hendricks +5 more
core +1 more source
Comparative efficacy and safety of anti-osteoporotic therapies for kidney transplant recipients: a systematic review and network meta-analysis. [PDF]
Front Endocrinol (Lausanne)Liu X +7 more
europepmc +1 more source
Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients" [PDF]
Nazım Can Demircan
openalex +1 more source
Sarcopenia as a Potential Risk Factor for Denosumab-Related Osteonecrosis of the Jaw in Asian Prostate Cancer Patients with Bone Metastases. [PDF]
Diagnostics (Basel)Mizushima S +7 more
europepmc +1 more source
SEOM Clinical Guideline for bone metastases from solid tumours (2016) [PDF]
, 2016 core +1 more source
Osteoporosis in men: epidemiology and treatment with denosumab
, 2014 Sidlauskas KM, Sutton EE, Biddle MA
openalex +1 more source
Rebound Hypercalcemia After Denosumab Cessation in Adult Fibrous Dysplasia: A Case Report and Clinical Alert. [PDF]
Case Rep EndocrinolLiu D, Chen J, Chen H, Hu W, Lin J.
europepmc +1 more source